Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Lip GY, Rasmussen LH, Olsson SB, Zetterstrand S, Stahre C, Bylock A, Aunes-Jansson M, Eriksson U, Wåhlander K; Steering Committee. Lip GY, et al. Among authors: wahlander k. Thromb Res. 2011 Feb;127(2):91-9. doi: 10.1016/j.thromres.2010.11.012. Epub 2010 Dec 18. Thromb Res. 2011. PMID: 21172721 Clinical Trial.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF; Steering Committee. Lip GY, et al. Eur Heart J. 2009 Dec;30(23):2897-907. doi: 10.1093/eurheartj/ehp318. Epub 2009 Aug 18. Eur Heart J. 2009. PMID: 19690349 Free PMC article. Clinical Trial.
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, Wåhlander K. Olsson SB, et al. Among authors: wahlander k. Thromb Haemost. 2010 Mar;103(3):604-12. doi: 10.1160/TH09-07-0509. Epub 2010 Jan 13. Thromb Haemost. 2010. PMID: 20076850 Clinical Trial.
Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Wolzt M, Eriksson UG, Gouya G, Leuchten N, Kapiotis S, Elg M, Schützer KM, Zetterstrand S, Holmberg M, Wåhlander K. Wolzt M, et al. Among authors: wahlander k. Thromb Res. 2012 Apr;129(4):e83-91. doi: 10.1016/j.thromres.2011.08.018. Epub 2011 Sep 16. Thromb Res. 2012. PMID: 21925716 Clinical Trial.
39 results